Skip to main content

CORRECTION article

Front. Pharmacol., 23 June 2023
Sec. Pharmacology of Anti-Cancer Drugs

Corrigendum: Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels

Peiwen Li&#x;Peiwen Li1Xiaohui Tian&#x;Xiaohui Tian2Gongxin WangGongxin Wang3Enshe Jiang
Enshe Jiang4*Yanming Li
Yanming Li1*Guoliang Hao
Guoliang Hao3*
  • 1Department of Cardiology, Huaihe Hospital of Henan University, Kaifeng, China
  • 2Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, China
  • 3Department of Research, Scope Research Institute of Electrophysiology, Kaifeng, China
  • 4Institute of Nursing and Health, Henan University, Kaifeng, China

A Corrigendum on
Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels

by Li P, Tian X, Wang G, Jiang E, Li Y and Hao G (2023). Front. Pharmacol. 14:1177003. doi: 10.3389/fphar.2023.1177003

In the published article, there was an error in affiliation 1. Instead of “School of Clinical Medicine, Henan University, Kaifeng, China”, it should be “Department of Cardiology, Huaihe Hospital of Henan University, Kaifeng, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: osimertinib, QT prolongation, cardiac electrophysiology, delayed conduction, ion channel

Citation: Li P, Tian X, Wang G, Jiang E, Li Y and Hao G (2023) Corrigendum: Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels. Front. Pharmacol. 14:1242042. doi: 10.3389/fphar.2023.1242042

Received: 18 June 2023; Accepted: 19 June 2023;
Published: 23 June 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Li, Tian, Wang, Jiang, Li and Hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Enshe Jiang, esjiang@gmail.com; Yanming Li, yanminglee@163.com; Guoliang Hao, guoliang.hao@epscopelab.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.